Business Wire

THALES

3.11.2021 14:02:06 CET | Business Wire | Press release

Share
SWAP Launches Modern Payment Security Infrastructure with Thales to Accelerate Route to Market

In partnership with First Tech, global technology company Thales today announced it has helped venture capital-backed financial service provider SWAP launch its modern digital payment infrastructure. With Thales’s cloud-based payment transaction security solution, SWAP will deliver financial infrastructure technologies faster and more effectively to its banking-as-a-service customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211103005068/en/

Banking-as-a-Service
SWAP, a venture capital-backed financial service provider, was founded in 2018 to support fintech and service providers in the adoption of financial technology in response to demand across all sectors – from marketplaces to ride sharing – for more reliable transaction processing and expanded financial and payment services.

However, company expansion and customer satisfaction relied on in-built compliance with Payment Card Industry Data Standards (PCI DSS). As a start-up, SWAP wasn’t able to implement the entire technological infrastructure needed: a secure room would have slowed and complicated the launch process, and ultimately, SWAP needed to be able to provide accelerated, scalable, certified access to the market. First Tech and Thales’ solution grants SWAP the scalability and PCI certification it needs to grow as its customers do.

“Our solution, delivered collaboratively with First Tech, has proved instrumental in helping SWAP rapidly launch its product to market. SWAP’s lack of legacy systems meant that the team could leapfrog to providing the secure digital services their customers needed in a short amount of time, and this has translated to success for both SWAP and their customers. Thales has a rich heritage in being a trusted provider of solutions that protect the data and services businesses and end-users rely on. We look forward to continuing to support SWAP and its customers in their impressive growth,” said Todd Moore, VP Encryption Products at Thales.

Driving growth
First Tech’s hosted payShield Hardware Security Module (HSM) offers SWAP a cloud-based service with HSM off premises. Thales’ market-leading HSMs are highly scalable, providing the flexibility and agility needed to support SWAP in its future growth. The environment includes a secure room for insertion of keys, the support of trained professionals, team training, consultancy, and services.

Bruno Napolitano, CISO Security, Risk, and Fraud at SWAP explained, “Thales payShield 10K is considered the benchmark for payment HSMs, with an excellent performance and several global certifications that prove the reliability of the solution for PCI compliance. In fact, our credit card partner has confirmed this was the fastest implementation of card issuance they’ve undertaken in the past 15 years, which is testament to the solution at hand. This speed to market has already made a huge impact on our growth, and since launch, we’ve seen a four-fold increase in our customer portfolio. Looking ahead, we expect to accelerate our growth by 30% to 40% per year, always counting on the support from First Tech and Thales.”

Edmar Siqueira, Head of innovation, Digital Payments at First Tech added: “By working in tandem with Thales, we’ve been able to provide SWAP with a remote HSM management system which enables their business and their customers to benefit from operational cost savings, greater agility, and on-demand key management. Importantly, the success of this solution has been driven by both the strength of the product and the commitment from all parties to ensuring that the implementation process delivered a full-rounded understanding which will continue to serve SWAP well as it grows.

A bout Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.

PLEASE VISIT
Thales Group
Security

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye